Currently, the next generation of SLATE targeting only 4 KRAS mutations is being evaluated in combination with nivolumab and ipilimumab in advanced or metastatic NSCLC, microsatellite stable colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors in a phase 2 study (NCT03953235). Here, KRAS is linked to pancreatic neoplasm.